Results 181 to 190 of about 241,664 (350)
Implicit Options in Life Insurance: Valuation and Risk Management [PDF]
Nadine Gatzert, Hato Schmeiser
openalex +1 more source
Cotargeting EGFR and STAT3 with Erlotinib and TTI‐101 impairs both 2D and 3D growth of ETV1‐overexpressing prostate cancer cells by disrupting a self‐sustaining ETV1–EGFR positive feedback loop that promotes EGFR and STAT3 expression and phosphorylation (activation).
Elsa Gomes Paiva+5 more
wiley +1 more source
Geometric tools for the valuation of performance-dependent options [PDF]
Thomas Gerstner, Markus Holtz
openalex +1 more source
Non‐small cell lung cancer targeted treatment is limited to a few known genetic alterations, with few alternatives in advanced treatment lines. To direct treatment decisions by drug sensitivity testing (DST), this study compared several methods for tumor cell isolation from malignant effusions, pointing to repeated CD45+ cell depletion for effective ...
Navit Mooshayef+10 more
wiley +1 more source
The role of the right valuation method in setting the firm's break-even price for mpox (and other) vaccines. [PDF]
Engelen PJ, Cassimon D.
europepmc +1 more source
Human cytomegalovirus infection is common in normal prostate epithelium, prostate tumor tissue, and prostate cancer cell lines. CMV promotes cell survival, proliferation, and androgen receptor signaling. Anti‐CMV pharmaceutical compounds in clinical use inhibited cell expansion in prostate cancer models in vitro and in vivo, motivating investigation ...
Johanna Classon+13 more
wiley +1 more source
In Search of a Neural Mechanism for Domain-General Value Comparison in Decision Making. [PDF]
Samara A, Zada Z.
europepmc +1 more source
PMD5 VALUATION OF NEW DRUG APPLICATIONS OF PHARMACEUTICAL COMPANIES USING COMPOUND OPTION MODELS
Danny Cassimon+3 more
openalex +1 more source
The Sequential Compound Option Pricing with Random Interest Rate and Application to Project Valuation [PDF]
Meng-Yu Lee, Fang Bo Yeh, An‐Pin Chen
openalex +1 more source